Stay updated on Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check30 days agoNo Change Detected
- Check38 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check45 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check66 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant revision.SummaryDifference0.2%
- Check88 days agoChange DetectedThe latest updates include the posting of results on December 19, 2024, featuring key metrics such as a 1-year relapse-free survival rate and median overall survival, along with new reporting dates and helpful links, while previous submissions and details regarding recurrence detection methods have been removed.SummaryDifference10%
Stay in the know with updates to Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page.